Intriguingly, DDAH1 autoantibodies have been detected in sera of prostate cancer patients and proposed as a new marker for a novel prostate cancer and benign hyperplasia diagnostic, improving on the traditional prostate specific antigen (PSA) test which often yields false-positive results (254). This evidence concerns the gene PROS1 and prostate carcinoma.